(PMGMU) – Globe Newswire
-
CORRECTION -- AEON Biopharma Announces Redemption of Public Warrants
-
AEON Biopharma Announces Redemption of Public Warrants
-
AEON Biopharma Reports Fourth Quarter and Full Year 2023 Financial Results
-
AEON Biopharma Announces Clinical Update and Productive End-of-Phase 2 Meeting with FDA on ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Migraine
-
AEON Biopharma Announces $15 Million Financing Transaction and Termination of Forward Purchase Agreements
-
AEON Biopharma Presents Positive Clinical and Pre-clinical Data for ABP-450 (prabotulinumtoxinA) in Treating Cervical Dystonia and PTSD, Respectively, at a Leading Neurotoxin Conference
-
AEON Biopharma Completes Enrollment in Phase 2 Study of ABP-450 (prabotulinumtoxinA) for Preventive Treatment of Chronic Migraine
-
AEON Biopharma Reports Third Quarter 2023 Financial Results
-
AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine
-
AEON Biopharma Presents Positive Results from Phase 2 Clinical Trial of ABP-450 (prabotulinumtoxinA) in Cervical Dystonia at the International Parkinson and Movement Disorders Society Congress®
-
AEON Biopharma Receives Notice of Allowance from USPTO for a Patent Covering Use of Botulinum Toxins to Treat Migraine Headache
-
Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma
-
AEON Biopharma Announces Closing of Business Combination with Priveterra Acquisition Corp. and Provides Pipeline Update
-
AEON Biopharma and Priveterra Announce Arrangement of Up to $125 Million of Financing in Connection with Proposed Business Combination
-
AEON Biopharma and Priveterra Acquisition Corp. Announce Additional Capital Commitment from Existing Investors for at Least $20 Million
-
AEON Biopharma Completes Enrollment in Phase 2 Trial of ABP-450 for Preventive Treatment of Episodic Migraine
-
RxSight Announces Appointments to its Board of Directors
-
RxSight Announces Appointments to its Board of Directors
-
Priveterra Acquisition Corp. Receives Expected Notification from Nasdaq Related to Delayed Quarterly Report
-
Priveterra Acquisition Corp. Announces the Separate Trading of its Common Stock and Warrants, Commencing April 1, 2021
-
Priveterra Acquisition Corp. Announces Closing of $276 Million Initial Public Offering
-
Priveterra Acquisition Corp. Announces Closing of $276 Million Initial Public Offering
Back to PMGMU Stock Lookup
